Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
Jordi Navarro, Adrian Curran Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is one of the cornerstones to achiev...
Guardado en:
Autores principales: | Navarro J, Curran A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/09a0768bc0c648c2b541b7d45621f610 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley RD, et al.
Publicado: (2016) -
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy
por: von Hentig N
Publicado: (2015) -
Mechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance
por: Manabu Aoki, et al.
Publicado: (2018) -
Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner SF, et al.
Publicado: (2019) -
Bioequivalence and food effect of a fixed‐dose combination of macitentan and tadalafil: Adaptive design in the COVID‐19 pandemic
por: Dénes Csonka, et al.
Publicado: (2021)